MarketCap
Facebook
X
Telegram
Xeris Pharmaceuticals Balance Sheet 2025-2011 | XERS
Brief overview of Xeris Pharmaceuticals's financial position
The balance sheet is assessed across five available annual reports spanning 2021 to 2025.
Assets added +26%, reaching $383.5 million from $304.4 million five periods earlier; annual growth near 6% remained solid.
Funding shifted toward liabilities: they gained +76.8%, compared with +26% for assets.
Equity funds just 3.6% of assets versus 31.3% previously. The balance sheet is sensitive to weaker results.
Each unit of equity supports 8.44x of net debt. This elevated load requires dependable cash generation.
The cash share moved from 22.1% to 29%. A higher figure generally provides more room in an adverse scenario.
The balance sheet includes a negative accumulated result of -$671.3 million. It should be assessed alongside historical profits and capital distributions.
What the balance sheet shows
Xeris Pharmaceuticals's financial structure calls for caution. Stronger equity, lower debt or restored liquidity would be needed to improve it.
Annual Balance Sheet Xeris Pharmaceuticals
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
116 M | 151 M | 127 M | 66.7 M | 20.8 M | 49.4 M | 38.8 M | -13.8 M | -42 M | -32.3 M | - | - | - | - | - |
Long Term Debt |
220 M | 217 M | 191 M | 187 M | 88.1 M | 87 M | 58.3 M | 31.9 M | - | - | - | - | - | - | - |
Long Term Debt Current |
6.23 M | 6.08 M | 3.5 M | 1.58 M | - | - | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | - | 97.2 M | 67.2 M | 34.4 M | 98 M | 62.9 M | - | - | - | - | - |
Total Current Liabilities |
110 M | 100 M | 95.2 M | 73.6 M | 79 M | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
370 M | 353 M | 329 M | 299 M | 209 M | 125 M | 94.6 M | 44.6 M | 103 M | 65.5 M | - | - | - | - | - |
Deferred Revenue |
- | - | - | - | - | - | - | 232 K | 234 K | 263 K | - | - | - | - | - |
Retained Earnings |
-671 M | -672 M | -617 M | -555 M | -460 M | -337 M | -246 M | -121 M | -60.6 M | -34 M | - | - | - | - | - |
Total Assets |
384 M | 323 M | 323 M | 345 M | 304 M | 159 M | 109 M | 120 M | 45 M | 33.5 M | - | - | - | - | - |
Cash and Cash Equivalents |
111 M | 71.6 M | 67.4 M | 122 M | 67.3 M | - | - | - | - | - | - | - | - | - | - |
Book Value |
13.7 M | -29.6 M | -6.78 M | 45.2 M | 95.2 M | 33.8 M | 14.4 M | 75.4 M | -57.8 M | -31.9 M | - | - | - | - | - |
Total Shareholders Equity |
13.7 M | -29.6 M | -6.78 M | 45.2 M | 95.2 M | 33.8 M | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Quarterly Balance Sheet Xeris Pharmaceuticals
| 2026-Q2 | 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
189 M | 221 M | 219 M | 219 M | 218 M | 217 M | 216 M | 230 M | 230 M | 191 M | 190 M | 188 M | 188 M | 187 M | 139 M | 138 M | 138 M | 88.1 M | 87.7 M | - | - | 87 M | 87 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
422 M | 379 M | 371 M | 354 M | 351 M | 353 M | 349 M | 351 M | 346 M | 329 M | 324 M | 315 M | 291 M | 299 M | 248 M | 245 M | 241 M | 209 M | 134 M | - | - | 125 M | 125 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-700 M | -669 M | -682 M | -683 M | -681 M | -672 M | -667 M | -651 M | -636 M | -617 M | -604 M | -591 M | -572 M | -555 M | -542 M | -520 M | -494 M | -460 M | -409 M | - | - | -337 M | -337 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Assets |
412 M | 392 M | 370 M | 335 M | 315 M | 323 M | 321 M | 332 M | 337 M | 323 M | 328 M | 329 M | 321 M | 345 M | 303 M | 319 M | 338 M | 304 M | 131 M | - | - | 159 M | 159 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cash and Cash Equivalents |
122 M | 112 M | 91.6 M | 59.3 M | 58.4 M | 71.6 M | 59.2 M | 57.6 M | 62.7 M | 67.4 M | 46.1 M | 46.2 M | 51 M | 122 M | 84.1 M | 95.3 M | 104 M | 67.3 M | 59.5 M | 63.6 M | 66.6 M | 37.6 M | 37.6 M | - | - | 19.5 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Book Value |
-9.73 M | 13 M | -861 K | -19.3 M | -35.1 M | -29.6 M | -28.3 M | -19.3 M | -9.18 M | -6.78 M | 3.86 M | 13.6 M | 30 M | 45.2 M | 55 M | 73.9 M | 96.5 M | 95.2 M | -2.46 M | - | - | 33.8 M | 33.8 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Shareholders Equity |
-9.73 M | 13 M | -861 K | -19.3 M | -35.1 M | -29.6 M | -28.3 M | -19.3 M | -9.18 M | -6.78 M | 3.86 M | 13.6 M | 30 M | 45.2 M | 55 M | 73.9 M | 96.5 M | 95.2 M | -2.46 M | 19.9 M | 44.4 M | 33.8 M | 33.8 M | 24.4 M | 27.1 M | 14.4 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Balance Sheet is a fundamental financial report of Xeris Pharmaceuticals, providing a complete picture of the company’s financial position at a specific point in time. Unlike the income statement, which records the results of operations over a certain period, the balance sheet shows what assets the company owns, what liabilities it has to creditors, and what equity is available to the owners.
For an investor, the balance sheet is important because it allows assessing the company’s financial stability, understanding how much debt it carries, and how dependent it is on borrowed financing. It helps calculate key liquidity and leverage ratios. When analyzing, attention should be paid to the debt-to-equity ratio (Debt/Equity), the amount of cash on the balance sheet, and the ratio of current liabilities to liquid assets.
Features of balance sheet analysis- Vertical and horizontal analysis
Vertical analysis shows the structure of the balance sheet as a percentage of total assets or liabilities, while horizontal analysis shows the dynamics of changes over multiple periods. - Asset quality
It is important to evaluate not only the amount of assets but also their liquidity and realizability. - Accounting for off-balance sheet liabilities
Some liabilities may not be directly reflected in the balance sheet, which requires additional attention.
USA
Canada
China
Britain
France
Israel
Germany
Russia
Belgium
Cayman-islands
